Medline Analysts Boost Their Forecasts Following Q4 Results

by | Feb 26, 2026 | General

Medline Inc (NASDAQ:MDLN) reported mixed results for the fourth quarter on Wednesday.

The company posted a quarterly loss of 1 cent per share which missed the analyst consensus estimate of earnings of 18 cents per share. The company reported quarterly sales of $7.787 billion which beat the analyst consensus estimate of $7.547 billion.

“We delivered strong fourth quarter results, concluding a successful 2025 with $2.4 billion in total new customer signings,” said Jim Boyle, Chief Executive Officer of Medline. “This performance reflects the confidence customers place in our value, service and reliability, and our unique capability to support health systems across the entire continuum of care.”

Medline shares gained 3.4% to trade at $49.80 on Thursday.

These analysts made changes to their price targets on Medline following earnings announcement.

  • Evercore ISI Group analyst Elizabeth Anderson maintained Medline with an Outperform rating and raised the price target from $50 to $55.
  • RBC Capital analyst Ryan Halsted maintained the stock with an Outperform rating and raised the price target from $47 to $53.
  • BMO Capital analyst Sean Dodge maintained Medline with an Outperform rating and raised the price target from $45 to $54.
  • UBS analyst Kevin Caliendo maintained the stock with a Buy and raised the price target from $48 to $57.

Considering buying MDLN stock? Here’s what analysts think:

Photo via Shutterstock